atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917
Posted:
Atai Life Sciences a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and its subsidiary GABA Therapeutics, announced final positive results from a Phase 1 clinical trial of GRX-917 that were previously announced as preliminary results during atai’s R&D day. Read more here.
Helping medical device companies navigate quality, compliance and regulatory pathways with confidence
Bringing a medical device to market requires more than innovative technology. Successful commercialisation depends on robust quality systems, effective risk management and a clear understanding of complex regulatory…
Discover Canada’s healthcare technology leaders connecting with the UK health and life sciences ecosystem
Healthcare innovation is increasingly shaped by international collaboration. By bringing together expertise from different markets, healthcare systems can accelerate the development, validation and adoption of technologies…